当前位置:首页 > 报告详情

Avantor_2026-JPM-HC-Conference-Presentation_vFINAL4.pdf

上传人: 明**** 编号:1069664 2026-01-17 14页 1.93MB

1、Emmanuel LignerJanuary 14,2026President and CEO44th AnnualJ.P.MorganHealthcare ConferenceDisclaimerThis presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are subject to the safe

2、harbor created thereby under the Private Securities Litigation Reform Act of 1995.All statements other than statements of historical fact included in this presentation are forward-looking statements.Forward-looking statements discuss our current expectations and projections relating to our financial

3、 condition,results of operations,plans,objectives,future performance and business.These statements may be preceded by,followed by or include the words“aim,”“anticipate,”“believe,”“estimate,”“expect,”“forecast,”“intend,”“likely,”“outlook,”“plan,”“potential,”“projection,”“continue,”“goal,”“objective,”

4、“opportunity,”“near-term,”“long-term,”“assumption,”“project,”“guidance,”“target,”“trend,”“seek,”“can,”“could,”“may,”“should,”“would,”“will,”the negatives thereof and other words and terms of similar meaning.Forward-looking statements are inherently subject to risks,uncertainties and assumptions;they

5、 are not guarantees of performance.You should not place undue reliance on these statements.We have based these forward-looking statements on our current expectations and projections about future events.Although we believe that our assumptions made in connection with the forward-looking statements ar

6、e reasonable,we cannot assure you that the assumptions and expectations will prove to be correct.Factors that could contribute to these risks,uncertainties and assumptions include,but are not limited to,the factors described in“Risk Factors”in our most recent annual report on Form 10-K and subsequen

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司概况**:Avantor为全球180个国家30万客户 locations提供服务,供应前20大制药公司,85%产品用于前20大商业化生物制剂,全球员工约13,500人。 2. **战略重点**:通过强化制造与供应链、优化人才与问责、简化运营、调整组合及升级市场策略推动业务复兴。 3. **财务指标**:2025年Q3调整后净杠杆率3.1倍,计划2026年投入约2000万美元更换老旧设备,并优先偿还债务及回购股票(500万授权额度)。 4. **非GAAP指标**:使用调整后EBITDA、EPS、运营利润率、自由现金流及有机收入增长等辅助评估业绩,详见附录。 5. **风险提示**:前瞻性声明基于当前预期,存在不确定性,需参考10-K及10-Q报告中的风险因素。
**Avantor前景如何?** **非GAAP指标有何用?** **债务策略是否有效?**
客服
商务合作
小程序
服务号
折叠